• Mar. 10, 2015, 4:20 PM
    • Zogenix (NASDAQ:ZGNX) enters into an agreement to sell its Zohydro ER business to Pernix Therapeutics (NASDAQ:PTX) for an upfront fee of $100M plus regulatory and sales milestones of up to $283.5M. The transaction includes the Zogenix sales organization and other select employees.
    • The deal enables Zogenix to focus its development efforts on its late-stage CNS pipeline including the Orphan Drug-designated ZX008 for the treatment of Dravet syndrome and Relday, a long-acting injectable formulation of risperidone for the maintenance treatment of schizophrenia.
    • Zogenix will host a conference call this afternoon at 4:30 pm ET to discuss the deal.
    Mar. 10, 2015, 4:20 PM | 10 Comments